Category Press Releases

Neurogene Names Christy Shafer as Chief Commercial Officer and Adds Christine Mikail, J.D., to Board of Directors

Neurogene Announces Christy Shafer as Chief Commercial Officer and Appoints Christine Mikail, J.D., to Its Board Neurogene Inc. has announced key leadership additions as it advances its mission to develop transformative therapies for rare neurological diseases. The company has appointed…

Read MoreNeurogene Names Christy Shafer as Chief Commercial Officer and Adds Christine Mikail, J.D., to Board of Directors

Bicycle Therapeutics Highlights Nuzefatide Pevedotin and EphA2 Pipeline Progress at AACR 2026

Bicycle Therapeutics Shares Pipeline Update on Nuzefatide Pevedotin and EphA2 Programs at AACR 2026 Bicycle Therapeutics has unveiled a comprehensive set of updates from its EphA2-targeting oncology pipeline at the American Association for Cancer Research Annual Meeting, highlighting growing clinical…

Read MoreBicycle Therapeutics Highlights Nuzefatide Pevedotin and EphA2 Pipeline Progress at AACR 2026

Zai Lab Highlights Preclinical Data Showing ZL-1503 Delivers Rapid Itch Relief and Anti-Inflammatory Effects in Atopic Diseases

Zai Lab shares preclinical data showing ZL-1503 delivers rapid itch relief and reduces inflammation in atopic diseases Zai Lab Limited has announced promising new preclinical findings for ZL-1503, its internally developed IL-13/IL-31Rα bispecific antibody, highlighting the therapy’s potential to address…

Read MoreZai Lab Highlights Preclinical Data Showing ZL-1503 Delivers Rapid Itch Relief and Anti-Inflammatory Effects in Atopic Diseases

Drug Farm to Present Encouraging Phase 1b Results for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™ Drug Farm has announced promising early clinical and immunologic data from its ongoing Phase 1b study evaluating DF-003, a first-in-class oral inhibitor…

Read MoreDrug Farm to Present Encouraging Phase 1b Results for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™
WuXi Biologics

WuXi Biologics Secures ISO 13485 Certification for Drug–Device Development and Manufacturing

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug–Device Combination Product Development and Manufacturing WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO 13485:2016 Medical Device Quality…

Read MoreWuXi Biologics Secures ISO 13485 Certification for Drug–Device Development and Manufacturing

Invivoscribe Launches PrepQuant™ System to Streamline Sample Preparation Workflows

Invivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that…

Read MoreInvivoscribe Launches PrepQuant™ System to Streamline Sample Preparation Workflows
AccurKardia

AccurKardia Signs Multi-Year Deal with Specialized Medical to Enhance Cardiac Monitoring Operations

AccurKardia Announces Multi-Year Agreement with Specialized Medical to Power its State-of-the-Art Cardiac Monitoring Operations AccurKardia, an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced a multi-year agreement with Specialized Medical. Under this partnership, AccurKardia’s…

Read MoreAccurKardia Signs Multi-Year Deal with Specialized Medical to Enhance Cardiac Monitoring Operations
Cabaletta

First Patients Receive Cabaletta Bio’s Rese-cel Produced Using Cellares’ Automated Cell Shuttle™ Platform

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.’s (“Cabaletta Bio” or “Cabaletta”) (Nasdaq: CABA) investigational CAR T cell therapy…

Read MoreFirst Patients Receive Cabaletta Bio’s Rese-cel Produced Using Cellares’ Automated Cell Shuttle™ Platform
Kashiv

Kashiv BioSciences Bolsters Leadership Team with New COO and SVP of Regulatory Affairs

Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny…

Read MoreKashiv BioSciences Bolsters Leadership Team with New COO and SVP of Regulatory Affairs